Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Crow, T J
Johnstone, E C
Longden, A
Owen, F
and
Riley, G
1977.
The Role of Dopamine in the Antipsychotic Effect and the Pathogenesis of Schizophrenia.
Proceedings of the Royal Society of Medicine,
Vol. 70,
Issue. 10_suppl,
p.
15.
Cotes, P. Mary
Crow, T. J.
Johnstone, Eve C.
Bartlett, W.
and
Bourne, Rachel C.
1978.
Neuroendocrine changes in acute schizophrenia as a function of clinical state and neuroleptic medication.
Psychological Medicine,
Vol. 8,
Issue. 4,
p.
657.
Crow, T. J.
1978.
Clinical Research Centre Division of Psychiatry 1974–1977.
Psychological Medicine,
Vol. 8,
Issue. 3,
p.
515.
Joseph, Michael H.
Frith, Christopher D.
and
Waddington, John L.
1979.
Dopaminergic mechanisms and cognitive deficit in schizophrenia.
Psychopharmacology,
Vol. 63,
Issue. 3,
p.
273.
Kleinman, Joel E.
Potkin, Steven
Rogol, Alan
Buchsbaum, Monte S.
Murphy, Dennis L.
Gillin, J. Christian
Nasrallah, Henry A.
and
Wyatt, Richard Jed
1979.
A Correlation Between Platelet Monoamine Oxidase Activity and Plasma Prolactin Concentrations in Man.
Science,
Vol. 206,
Issue. 4417,
p.
479.
Wilson, JD
King, DJ
and
Sheridan, B
1979.
Plasma prolactin levels before and during propranolol treatment in chronic schizophrenia..
British Journal of Clinical Pharmacology,
Vol. 7,
Issue. 3,
p.
313.
SHEARD, MICHAEL H.
1979.
Neuro-Psychopharmacology.
p.
313.
Johnstone, EC
and
Ferrier, IN
1980.
Neuroendocrine markers of CNS drug effects..
British Journal of Clinical Pharmacology,
Vol. 10,
Issue. 1,
p.
5.
King, D. J.
Turkson, S. N. A.
Liddle, J.
and
Kinney, C. D.
1980.
Some Clinical and Metabolic Aspects of Propranolol in Chronic Schizophrenia.
British Journal of Psychiatry,
Vol. 137,
Issue. 5,
p.
458.
Brown, P. J.
Cleghorn, J. M.
Brown, G. M.
and
Blackall, Mary Helen
1980.
The Neuroendocrinology of Schizophrenia.
International Journal of Mental Health,
Vol. 9,
Issue. 3-4,
p.
108.
Meitzer, Herbert Y.
1980.
Effect of Psychotropic Drugs on Neuroendocrine Function.
Psychiatric Clinics of North America,
Vol. 3,
Issue. 2,
p.
277.
Johnstone, E. C.
and
Ferrier, I. N.
1981.
Methods in Clinical Pharmacology—Central Nervous System.
p.
3.
Brown, Gregory M.
Cleghorn, John M.
Ettigi, Prakash G.
and
Brown, Peter
1981.
Neuroendocrine Regulation and Altered Behaviour.
p.
339.
Brown, Gregory M.
Cleghorn, John M.
Ettigi, Prakash G.
and
Brown, Peter
1981.
Neuroendocrine Regulation and Altered Behaviour.
p.
339.
Ferrier, I. N.
Cotes, P. M.
Crow, T. J.
and
Johnstone, E. C.
1982.
Gonadotrophin secretion abnormalities in chronic schizophrenia.
Psychological Medicine,
Vol. 12,
Issue. 2,
p.
263.
Checkley, Stuart
1982.
Clinical Neuroendocrinology.
p.
265.
FERRIER, I. N.
ARENDT, J.
JOHNSTONE, E. C.
and
CROW, T. J.
1982.
REDUCED NOCTURNAL MELATONIN SECRETION IN CHRONIC SCHIZOPHRENIA: RELATIONSHIP TO BODY WEIGHT.
Clinical Endocrinology,
Vol. 17,
Issue. 2,
p.
181.
1982.
Antipsychotic drug therapy and sexual dysfunction in men.
American Journal of Psychiatry,
Vol. 139,
Issue. 5,
p.
633.
Meltzer, Herbert Y.
and
Busch, Daniel
1983.
Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: Implications for the dopamine hypothesis.
Psychiatry Research,
Vol. 9,
Issue. 4,
p.
285.
Rodnight, Richard
1983.
Schizophrenia: Some Current Neurochemical Approaches.
Journal of Neurochemistry,
Vol. 41,
Issue. 1,
p.
12.